Abstract

BackgroundThere has been debate about the cost-effectiveness of photodynamic therapy (PDT), a treatment for neovascular age-related macular degeneration. We have been monitoring trends for the provision of PDT in the UK National Health Service. The fourth annual 'tracker' survey took place as definitive National Institute for Clinical Excellence (NICE) guidance was issued. We assessed trends in PDT provision up to the point of release of the NICE guidance and identified likely sources of pressure on ophthalmologists to provide PDT.MethodsNational postal questionnaire survey of clinicians with potential responsibility for PDT provision. The survey explored reported local provision, beliefs about the effectiveness of PDT and what sources of opinion might influence attitudes towards providing PDT.ResultsThe response rate was 73% (111/150). Almost half of the surveyed ophthalmology units routinely provided PDT, as part of a trend of steady growth in provision. The proportion of respondents who believed that further proof of effectiveness was required has also declined despite the absence of any new substantial evidence. Attitudes towards providing PDT were positive, on average, and were more strongly associated with perceived social pressure from local colleagues than from other sources. Local colleagues were seen as being most approving of PDT.ConclusionThose responsible for implementing the NICE guidance need to address ophthalmologists' beliefs about the evidence of effectiveness for PDT and draw upon supportive local individuals or networks to enhance the credibility of the guidance.

Highlights

  • There has been debate about the cost-effectiveness of photodynamic therapy (PDT), a treatment for neovascular age-related macular degeneration

  • The proportion of units reporting routine provision of PDT for patients with more than 50% classic sub-foveal choroidal neovascularisation (CNV) significantly increased over four years from 8.5% to 41% (p < 0.001), making this the most common reported

  • Local colleagues were seen as being most approving of PDT

Read more

Summary

Introduction

There has been debate about the cost-effectiveness of photodynamic therapy (PDT), a treatment for neovascular age-related macular degeneration. A subgroup analysis has shown a statistically significant benefit in the prevention of visual loss in people with wholly or predominantly classic choroidal neovascularisation (CNV). These findings contributed to pressure upon the UK National Health Service (NHS) from both patient and professional groups to make this therapy routinely available [5,6]. Concern about the cost-effectiveness of PDT [10] prompted the National Institute for Clinical Excellence (NICE) to undertake a technology appraisal of PDT. During the protracted course of the technology appraisal and subsequent appeals, there was evidence that ophthalmology units were establishing services or referring patients for PDT

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.